Handok, Inc.
KKRX:0023908,320.00
KRW
-70.00
(-0.83%)
ISIN
KR7002390003
Return %
Stock
S&P 500
1Y
-28.28
14.39
3Y
-29.43
81.42
5Y
-65.76
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Cho Jae-cheon
- Full Time Employees
- 951
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 132 Teheran-ro Seoul SL South Korea 06235
- IPO Date
- Jun 30, 1976
- Website
- handok.co.kr
- Similar Companies
- Business
- HANDOK Inc. is a South Korea-based pharmaceutical and healthcare company founded in 1954 and headquartered in Seoul. It specializes in the development, manufacture, and marketing of prescription (ETC) and over-the-counter (OTC) drugs; medical devices; diagnostic reagents; vaccines; and healthcare products including food supplements and medical nutrition under brands such as NatureSet and Culturelle. The company’s product portfolio covers key therapeutic areas including diabetes, cardiovascular diseases, rare and orphan diseases, oncology, musculoskeletal disorders, psychoneurotic diseases, and eye disorders. Notable pharmaceutical products include Amaryl for diabetes, Tritace for cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation disturbances, and Lasix for edema. HANDOK also manufactures and commercializes medical devices such as DENEX™, a renal denervation device for resistant hypertension approved with CE marking. Recent major developments include the creation of a wholly owned subsidiary, Handok Healthcare, consolidating its consumer healthcare business and integrating Theravalues, a Japanese functional ingredient firm acquired in 2016. This move aims to strengthen vertical integration and expand the company’s footprint in the global functional food and wellness markets through proprietary ingredients like teracurmin. In addition, HANDOK formed a joint venture with Swedish Orphan Biovitrum AB (Sobi) to commercialize and distribute rare disease medicines in South Korea, reflecting a strategic expansion into rare diseases. HANDOK has also established strategic collaborations with biotechnology companies such as AUM Biosciences for developing targeted oncology therapeutics. Furthermore, the company launched Handok-Kalos Medical, an R&D subsidiary focused on advancing and globally distributing innovative medical devices like DENEX™. HANDOK continues to pursue growth through strategic partnerships, product launches, and diversification into diagnostics, vaccines, and wellness sectors, while maintaining a significant presence in the South Korean pharmaceutical market and outward expansion efforts. The company operates primarily in South Korea with exports to markets including Thailand, Dubai, Russia, Hungary, UAE, Philippines, and Singapore. HANDOK's legacy includes a long-standing partnership history with global pharmaceutical companies such as Hoechst, Aventis, and Sanofi until 2012. The company also engages in real estate rental business as part of its diversified operations. It employs around 940 staff and reported a revenue base driven mainly by its pharmaceutical products and medical merchandise segments. HANDOK Inc. thereby positions itself as an integrated healthcare solutions provider with a comprehensive portfolio spanning pharmaceuticals, medical devices, diagnostics, vaccines, and consumer health products, enhanced by recent strategic expansions and product innovations.